Immunovant, Inc. is a clinical-stage immunology company that develops targeted therapies for autoimmune diseases. Its lead candidate, IMVT-1402, is a human monoclonal antibody that inhibits the neonatal fragment crystallizable receptor and is being developed for Graves' disease, rheumatoid arthritis, Sjögren's disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. Founded in 2018, the company is based in Durham, North Carolina, and operates as a subsidiary of Roivant Sciences Ltd.
Immunovant Discontinues IMVT-1402 Lupus Program After Phase 2b Miss
Immunovant said its proof-of-concept Phase 2b trial of IMVT-1402 in cutaneous lupus erythematosus missed the primary efficacy goal, and the company is discontinuing the program in that indication. The setback lands at a sensitive moment for the biotech, whose shares last closed at US$33.49 after a 1-day share price return of 0.57%, while the 7-day share price return is down 9.92% and the 30-day share price return is down 18.71%. Longer term momentum remains positive, with a year-to-date share price return of 29.26% and a 1-year total shareholder return of 108.53%. The widely followed fair value narrative centers on $48.07 per share, leaving the current quote well below that framework and putting extra weight on the long term pipeline story behind IMVT-1402. The fully enrolled D2T RA study for IMVT-1402, upsized to 170 patients, reflects strong physician and patient engagement that could support broader adoption in difficult to treat autoimmune populations over time.
Immunovant reported a cash balance of $797.8 million as of June 30, 2026, which management stated provides a runway to the potential commercial launch of IMVT-1402 in Graves' disease. Research and development expenses were $142.6 million for the quarter, compared to $101.2 million in the prior year, primarily due to increased clinical trial activities for IMVT-1402 and contract manufacturing costs. The company reported a net loss of $153.2 million, or $0.75 per common share, for the three months ended June 30, 2026, and a non-GAAP net loss of $139.4 million excluding $13.8 million in non-cash stock-based compensation. Management expects topline data from the proof-of-concept trial in cutaneous lupus erythematosus in the second half of 2026, and topline data for the potentially registrational trials in Graves' disease and myasthenia gravis in calendar year 2027. Roivant, the parent company, received an upfront payment of $950 million from the Moderna settlement, with $770 million allocated to Genevant and the remainder to Arbutus, and reported a cash balance of just under $4 billion prior to the receipt of the Moderna settlement funds.
Immunovant to report first quarter 2026 results and business update on August 6
Immunovant announced it will report financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Majority stockholder Roivant Sciences will host a conference call and webcast at 8:00 a.m. Eastern Time that same day, which will include a business update for Immunovant. The archived webcast will be available on Immunovant's website after the call.
Kuehn Law investigates Immunovant officers and directors for potential fiduciary breaches
Kuehn Law, PLLC is investigating whether certain officers and directors of Immunovant, Inc. breached their fiduciary duties to shareholders. The shareholder litigation law firm announced the investigation on July 20, 2026, focusing on potential self-dealing. Long-term Immunovant stockholders may be entitled to damages and corporate governance reforms. Shareholders are encouraged to contact Justin Kuehn, Esq. at justin@kuehn.law or by calling (833) 672-0814 for a free consultation with no obligation.
Cutaneous Lupus Erythematosus Market to Grow at 8% CAGR Through 2036, Reaching USD 650 Million in 2025
The cutaneous lupus erythematosus market across the seven major markets was valued at USD 650 million in 2025 and is projected to expand at a compound annual growth rate of 8% during the 2026 to 2036 forecast period, according to a new report from DelveInsight. The United States accounted for the largest share of the market in 2025, representing around 60% of total diagnosed prevalent cases in the seven major markets, which also include the EU4 countries Germany, France, Italy, and Spain, the United Kingdom, and Japan. Antimalarials contributed over 50% of total annual revenue in 2025 across these markets. Growth is being driven by rising autoimmune disease prevalence, improved diagnosis, and a pipeline of emerging targeted therapies such as Litifilimab from Biogen, Daxdilimab from Amgen and Horizon Therapeutics, SOTYKTU from Bristol Myers Squibb, IMVT-1402 from Immunovant Sciences, VENT-03 from Ventus Therapeutics, CNTY-101 from Century Therapeutics, Anifrolumab from AstraZeneca, and Enpatoran from Merck. Biogen's Litifilimab received breakthrough therapy designation from the US FDA in January 2026 and reported positive Phase II results in March 2026, while Amgen announced positive Phase II results for Daxdilimab in discoid lupus erythematosus in 2026 and is considering advancing it to Phase III.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Demand
BIIB · Technology · Positive Litifilimab received FDA breakthrough therapy designation and positive Phase II results, driving pipeline optimism.
BIIB · Demand · Positive Biogen's Litifilimab received FDA breakthrough therapy designation and positive Phase II results, positioning it well in the expanding CLE market.
AMGN · Demand · Positive Amgen's Daxdilimab reported positive Phase II results and is advancing to Phase III, indicating strong pipeline progress in a growing market.
BMY · Technology · Positive SOTYKTU is mentioned as an emerging targeted therapy in the pipeline, contributing to market growth.
BMY · Demand · Positive Bristol Myers Squibb's SOTYKTU is mentioned as an emerging therapy in the growing CLE market, benefiting from rising prevalence and diagnosis.
IMVT · Demand · Positive Immunovant's IMVT-1402 is listed as an emerging targeted therapy in the expanding CLE market.
Immunovant shares rise 3.6% since wider-than-expected quarterly loss
Immunovant shares have gained about 3.6% over the past month, outperforming the S&P 500, following a fourth-quarter 2026 net loss of 73 cents per share that was wider than the Zacks Consensus Estimate of a 60-cent loss. Research and development expenses climbed 51.9% to $142.3 million, driven by clinical activities for IMVT-1402 and $39 million in costs tied to the discontinuation of batoclimab. Cash and cash equivalents stood at approximately $902.1 million as of March 31, 2026, which the company expects will fund operations through the commercial launch of IMVT-1402 for GD. Analysts have been revising estimates downward, and the stock currently carries a Zacks Rank #3, or Hold, with an aggregate VGM Score of F.
IMVT · Capital · Neutral Wider-than-expected loss and rising R&D costs are negative, but stock rose 3.6% over the past month, possibly due to other factors; net effect unclear.
Chronic Inflammatory Demyelinating Polyneuropathy Market Expected to Grow Through 2036 on Advancing Clinical Research
The chronic inflammatory demyelinating polyneuropathy treatment market is projected to grow positively by 2036 across leading markets, driven by an expanding diagnosed patient population, improved disease awareness, and the anticipated introduction of novel mechanism-based therapies. The United States accounted for the largest market size in 2025 compared with the EU4 countries, the United Kingdom, and Japan. Key companies advancing new treatments include Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, and Takeda, with promising pipeline therapies such as Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, and TAK-411. The prevalence of CIDP is estimated at around 5 to 7 cases per 100,000 individuals in the UK, and the market is seeing increased demand for targeted and long-acting therapies including subcutaneous immunoglobulin formulations and FcRn inhibitors.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Demand
ARGX · Demand · Positive argenx is advancing Empasiprubart for CIDP, and the expanding market and need for novel therapies support its potential.
DNTH · Demand · Positive Dianthus Therapeutics is developing DNTH103, a promising pipeline therapy for CIDP, and the market growth driven by expanding patient population and awareness increases potential demand.
IMVT · Demand · Positive Immunovant is developing Batoclimab for CIDP, and the projected market growth and demand for targeted therapies benefit its pipeline.
4502.JP · Demand · Positive Takeda has pipeline candidates TAK-881 and TAK-411 for CIDP, and the growing market increases opportunity for these therapies.
SAN.PA · Demand · Positive Sanofi is developing Riliprubart for CIDP, and the market growth and demand for new treatments enhance its prospects.
Nuvig Therapeutics · Demand · Positive Nuvig Therapeutics is developing NVG-2089, a pipeline therapy for CIDP, and the article highlights growing patient population and demand for targeted therapies.
United States